156 related articles for article (PubMed ID: 27802009)
1. Impact of local treatment on overall survival of patients with metastatic prostate cancer: systematic review and meta-analysis.
Carneiro A; Baccaglini W; Glina FPA; Kayano PP; Nunes VM; Smaletz O; Bernardo WM; Carvalho IT; Lemos GC
Int Braz J Urol; 2017; 43(4):588-599. PubMed ID: 27802009
[TBL] [Abstract][Full Text] [Related]
2. Local Therapy Improves Survival in Metastatic Prostate Cancer.
Leyh-Bannurah SR; Gazdovich S; Budäus L; Zaffuto E; Briganti A; Abdollah F; Montorsi F; Schiffmann J; Menon M; Shariat SF; Fisch M; Chun F; Steuber T; Huland H; Graefen M; Karakiewicz PI
Eur Urol; 2017 Jul; 72(1):118-124. PubMed ID: 28385454
[TBL] [Abstract][Full Text] [Related]
3. Impact of Radiotherapy on Prognosis in Patients Diagnosed with Metastatic Prostate Cancer: A Systematic Review and Meta-Analysis.
Liu S; Wang XY; Huang TB; Ma XX; Xia ZZ; Tang LB; Zhao TS; Zhou GC
Urol Int; 2021; 105(5-6):370-379. PubMed ID: 33302278
[TBL] [Abstract][Full Text] [Related]
4. The Impact of Local Treatment on Overall Survival in Patients with Metastatic Prostate Cancer on Diagnosis: A National Cancer Data Base Analysis.
Löppenberg B; Dalela D; Karabon P; Sood A; Sammon JD; Meyer CP; Sun M; Noldus J; Peabody JO; Trinh QD; Menon M; Abdollah F
Eur Urol; 2017 Jul; 72(1):14-19. PubMed ID: 27174537
[TBL] [Abstract][Full Text] [Related]
5. Might definitive local therapy of the primary tumor improve the survival benefits of metastatic prostate cancer?-evidence from a meta-analysis.
Xiao M; Cong R; Zhang Q; Xiang W; Xiao H
Ann Palliat Med; 2020 May; 9(3):648-660. PubMed ID: 32312070
[TBL] [Abstract][Full Text] [Related]
6. Identifying optimal candidates for local treatment of the primary tumor among patients diagnosed with metastatic prostate cancer: a SEER-based study.
Fossati N; Trinh QD; Sammon J; Sood A; Larcher A; Sun M; Karakiewicz P; Guazzoni G; Montorsi F; Briganti A; Menon M; Abdollah F
Eur Urol; 2015 Jan; 67(1):3-6. PubMed ID: 25217422
[TBL] [Abstract][Full Text] [Related]
7. Might men diagnosed with metastatic prostate cancer benefit from definitive treatment of the primary tumor? A SEER-based study.
Culp SH; Schellhammer PF; Williams MB
Eur Urol; 2014 Jun; 65(6):1058-66. PubMed ID: 24290503
[TBL] [Abstract][Full Text] [Related]
8. Survival benefit of local versus no local treatment for metastatic prostate cancer-Impact of baseline PSA and metastatic substages.
Pompe RS; Tilki D; Preisser F; Leyh-Bannurah SR; Bandini M; Marchioni M; Gild P; Tian Z; Fossati N; Cindolo L; Shariat SF; Huland H; Graefen M; Briganti A; Karakiewicz PI
Prostate; 2018 Jul; 78(10):753-757. PubMed ID: 29663462
[TBL] [Abstract][Full Text] [Related]
9. The role of radical prostatectomy for the treatment of metastatic prostate cancer: a systematic review and meta-analysis.
Wang Y; Qin Z; Wang Y; Chen C; Wang Y; Meng X; Song N
Biosci Rep; 2018 Feb; 38(1):. PubMed ID: 29263146
[TBL] [Abstract][Full Text] [Related]
10. Addition of Docetaxel to Androgen Deprivation Therapy for Patients with Hormone-sensitive Metastatic Prostate Cancer: A Systematic Review and Meta-analysis.
Tucci M; Bertaglia V; Vignani F; Buttigliero C; Fiori C; Porpiglia F; Scagliotti GV; Di Maio M
Eur Urol; 2016 Apr; 69(4):563-573. PubMed ID: 26422676
[TBL] [Abstract][Full Text] [Related]
11. Treatment of the Primary Tumor in Metastatic Prostate Cancer: Current Concepts and Future Perspectives.
Bayne CE; Williams SB; Cooperberg MR; Gleave ME; Graefen M; Montorsi F; Novara G; Smaldone MC; Sooriakumaran P; Wiklund PN; Chapin BF
Eur Urol; 2016 May; 69(5):775-87. PubMed ID: 26003223
[TBL] [Abstract][Full Text] [Related]
12. Role of radical prostatectomy in metastatic prostate cancer: A review.
Metcalfe MJ; Smaldone MC; Lin DW; Aparicio AM; Chapin BF
Urol Oncol; 2017 Apr; 35(4):125-134. PubMed ID: 28190749
[TBL] [Abstract][Full Text] [Related]
13. Androgen Deprivation Therapy (ADT) Plus Docetaxel Versus ADT Alone in Metastatic Non castrate Prostate Cancer: Impact of Metastatic Burden and Long-term Survival Analysis of the Randomized Phase 3 GETUG-AFU15 Trial.
Gravis G; Boher JM; Joly F; Soulié M; Albiges L; Priou F; Latorzeff I; Delva R; Krakowski I; Laguerre B; Rolland F; Théodore C; Deplanque G; Ferrero JM; Culine S; Mourey L; Beuzeboc P; Habibian M; Oudard S; Fizazi K;
Eur Urol; 2016 Aug; 70(2):256-62. PubMed ID: 26610858
[TBL] [Abstract][Full Text] [Related]
14. Excellent results from high dose rate brachytherapy and external beam for prostate cancer are not improved by androgen deprivation.
Demanes DJ; Brandt D; Schour L; Hill DR
Am J Clin Oncol; 2009 Aug; 32(4):342-7. PubMed ID: 19398902
[TBL] [Abstract][Full Text] [Related]
15. Association between lactate dehydrogenase levels and oncologic outcomes in metastatic prostate cancer: A meta-analysis.
Li F; Xiang H; Pang Z; Chen Z; Dai J; Chen S; Xu B; Zhang T
Cancer Med; 2020 Oct; 9(19):7341-7351. PubMed ID: 32452656
[TBL] [Abstract][Full Text] [Related]
16. [Current multidisciplinary approaches for metastatic prostate cancer].
Satoh T; Ishiyama H
Nihon Rinsho; 2017 Apr; 75(4):620-625. PubMed ID: 30549869
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and Safety of Combined Androgen Deprivation Therapy (ADT) and Docetaxel Compared with ADT Alone for Metastatic Hormone-Naive Prostate Cancer: A Systematic Review and Meta-Analysis.
Botrel TE; Clark O; Lima Pompeo AC; Horta Bretas FF; Sadi MV; Ferreira U; Borges Dos Reis R
PLoS One; 2016; 11(6):e0157660. PubMed ID: 27308831
[TBL] [Abstract][Full Text] [Related]
18. Treatment of M1a/M1b prostate cancer with or without radical prostatectomy at diagnosis.
Moschini M; Morlacco A; Kwon E; Rangel LJ; Karnes RJ
Prostate Cancer Prostatic Dis; 2017 Mar; 20(1):117-121. PubMed ID: 28045114
[TBL] [Abstract][Full Text] [Related]
19. Androgen deprivation therapy plus docetaxel and estramustine versus androgen deprivation therapy alone for high-risk localised prostate cancer (GETUG 12): a phase 3 randomised controlled trial.
Fizazi K; Faivre L; Lesaunier F; Delva R; Gravis G; Rolland F; Priou F; Ferrero JM; Houede N; Mourey L; Theodore C; Krakowski I; Berdah JF; Baciuchka M; Laguerre B; Fléchon A; Ravaud A; Cojean-Zelek I; Oudard S; Labourey JL; Chinet-Charrot P; Legouffe E; Lagrange JL; Linassier C; Deplanque G; Beuzeboc P; Davin JL; Martin AL; Habibian M; Laplanche A; Culine S
Lancet Oncol; 2015 Jul; 16(7):787-94. PubMed ID: 26028518
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]